Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2019

View Archived Issues

Aspartylglycosamine as a potential new biochemical marker of NGLY1-CDDG

Imotope shows promise in EAE model

Methylation patterns, AI identify metastases

Mitochondria differ between cell types

EGPI-1 as a promising new anticancer agent that targets the eIF4E/eIF4G interface

p38Gamma as a novel therapeutic target in human colorectal cancer

Waking up sleeping Xs

Enrollment initiated in phase III study of NmCV-5

First volunteers dosed in phase I clinical program of IMU-935

Results presented from AFIRE study of rivaroxaban monotherapy versus combination therapy

Identification of a novel Mtb inhibitor BRD-8000.3 through large-scale chemical-genetics platform

Sichuan University reports phase I results for yogliptin

D-578 demonstrates antidepressant and anti-PTSD-like effects in vivo

Study finds microbe drives CRC, identifies therapeutic target

First-in-human study evaluates UB-312 in healthy subjects and patients with Parkinson's disease

Heidelberg Pharma's work in ETN MAGICBULLET project supported by new E.U. grant

Molecular Templates begins first-in-human study of MT-5111 in HER2-positive solid tumors

U.S. researchers patent HLA DQ8 ligands

SciFluor Life Sciences presents new integrin receptor antagonists

Genentech identifies new SCN9A blockers

Karus Therapeutics describes HDAC inhibitors

New cytokine biosynthesis inducers presented by 3M Pharmaceuticals

Onxeo reports initial data from first part of phase Ib DRIIV study of AsiDNA

Alzprotect cleared to begin French phase IIa trial of AZP-2006 in progressive supranuclear palsy

BeiGene studies BGB-A1217 with tislelizumab in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...